What question did this study set out to answer?

To investigate the role of neuropeptide Y in hypertension by measuring circulating levels of neuropeptide Y and noradrenaline in severe hypertension before and during treatment.

October 1, 1992Journal of Hypertension

Neuropeptide Y-like immunoreactivity and hypertension

View Full Paper

Ask AI

Bookmark

Why the study?

Does antihypertensive treatment normalize elevated neuropeptide Y-like immunoreactivity in patients with severe hypertension?

Key Points

To investigate the role of neuropeptide Y in hypertension by measuring circulating levels of neuropeptide Y and noradrenaline in severe hypertension before and during treatment.
Assessed circulating neuropeptide Y-like immunoreactivity (NPY-LI) and noradrenaline in patients with untreated severe hypertension (diastolic blood pressure > 120 mmHg) and age- and sex-matched controls.
Followed patients over a 12-month period during antihypertensive treatment with beta-blockers, diuretics, ACE inhibitors, or calcium antagonists.
Measured plasma NPY-LI by radioimmunoassay with rabbit antiserum and catecholamines via high-performance liquid chromatography with electrochemical detection.
Circulating NPY-LI was significantly higher in patients with severe hypertension compared to matched controls.
Elevated NPY-LI levels remained high for up to 12 months despite the successful reduction of blood pressure to acceptable levels.
Plasma noradrenaline levels were not increased before treatment, at 2–4 weeks, or throughout 2–12 months of therapy, and blood pressure did not correlate with NPY-LI or noradrenaline.

Structured PICO

Does antihypertensive treatment normalize elevated neuropeptide Y-like immunoreactivity in patients with severe hypertension?

Population

Patients with untreated, severe hypertension (diastolic blood pressure > 120 mmHg) and age- and sex-matched controls.

Intervention

Antihypertensive treatment (beta-adrenoceptor blockers, diuretics, angiotensin converting enzyme inhibitors, or calcium antagonists) over 12 months.

Comparator

Age- and sex-matched controls (at baseline).

Outcome

Circulating levels of neuropeptide Y-like immunoreactivity (NPY-LI) and noradrenaline.surrogate

Elevated neuropeptide Y-like immunoreactivity in severe hypertension may serve as a marker for increased sympathetic nervous system activity that is not normalized by standard antihypertensive therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Elevated NPY-LI may mark persistent sympathetic activity despite BP control; hypothesis-generating and should not yet change practice.

Cite This Study

Erlinge et al. (1992) studied this question.

synapsesocial.com/papers/6a89cf4cc89a2b4713ec7415 https://doi.org/10.1097/00004872-199210000-00016

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Neuropeptide Y-like immunoreactivity and hypertension

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Neuropeptide Y-like immunoreactivity and hypertension

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider